SCHEMBL4895208

SCHEMBL4895208

CC(=O)Nc1c(-c2ccc(F)cc2)c2ccccc2[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.61
POLB P06746 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPT P10636 1/20 0.61
PADI4 Q9UM07 5/20 0.57
MAPK14 Q16539 2/20 0.54
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
PTGS2 P35354 3/20 0.47
HSD17B10 Q99714 1/20 0.44
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
MAOA P21397 1/20 0.43
GSK3B P49841 1/20 0.43
ADK P55263 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14315935 0.77 ALDH1A1 (0.48) KDM4EALDH1A1MAPTPADI4MAPK14
SCHEMBL16814559 0.77 KDM4E (0.58) KDM4EPOLBALDH1A1MAPTPADI4
SCHEMBL15713617 0.76 MAPK14 (0.63) KDM4EALDH1A1MAPTPADI4MAPK14
SCHEMBL16814473 0.76 PADI4 (0.62) KDM4EPOLBALDH1A1MAPTPADI4
SCHEMBL16111849 0.75 POLB (0.62) KDM4EPOLBALDH1A1MAPTPADI4
SCHEMBL8273828 0.75 DPP4 (0.44) KDM4EALDH1A1PADI4MAPK14MEN1
Hydrochloric Acid SCHEMBL4893749 0.74 DPP4 (0.44) KDM4EALDH1A1PADI4MAPK14MEN1
Hydrochloric Acid SCHEMBL27694404 0.74 DPP4 (0.44) KDM4EALDH1A1PADI4MAPK14MEN1
SCHEMBL15194482 0.74 MAPT (0.77) KDM4EPOLBALDH1A1MAPTMAPK14
SCHEMBL4897721 0.74 MAPK14 (0.63) KDM4EALDH1A1MAPTPADI4MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-10 US disclosed
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-10 US disclosed
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-10 US disclosed
CN-101001841-A Tetrahydroquinolones and aza-analogues thereof useful as DPP-IV inhibitors for the treatment of diabetes ASTRAZENECA AB (SE) 2007-07-18 CN disclosed
EP-1758863-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES AstraZeneca AB (SE) 2007-03-07 EP disclosed
WO-2005123685-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-29 WO disclosed
WO-2005123685-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes DPP4, DPP8, DPP3 KDM4E 94/4885POLB 3228/4885ALDH1A1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.